Misplaced Pages

Genetex

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
The topic of this article may not meet Misplaced Pages's notability guidelines for companies and organizations. Please help to demonstrate the notability of the topic by citing reliable secondary sources that are independent of the topic and provide significant coverage of it beyond a mere trivial mention. If notability cannot be shown, the article is likely to be merged, redirected, or deleted.
Find sources: "Genetex" – news · newspapers · books · scholar · JSTOR (May 2018) (Learn how and when to remove this message)
This article relies excessively on references to primary sources. Please improve this article by adding secondary or tertiary sources.
Find sources: "Genetex" – news · newspapers · books · scholar · JSTOR (May 2018) (Learn how and when to remove this message)
(Learn how and when to remove this message)

GeneTex is a life science, biotechnology company that develops, licenses, and sells a product catalog of research reagents related to the study of the biomedical sciences. The company provides antibodies and proteins for use by academic and industry investigators involved in basic and translational research in biology and medicine.

GeneTex, Inc
Company typePrivate
IndustryBiotechnology, Life Sciences
Founded1997
FoundersJoel B. Baseman, Eva Y.-H. P. Lee, Wen-Hwa Lee, C. Kent Osborne
HeadquartersIrvine, CA
Areas servedInternational
ProductsResearch Antibodies, kits and assays for biological research
Number of employees50-200
Websitewww.genetex.com

In 2016, GeneTex together with antibody research companies Novus Biologicals, R&D Systems, and Atlas Antibodies joined the International Working Group on Antibody Validation (IWGAV) with the intention to help standardize best practices in antibody validation.

Recombinant monoclonal antibody technology

GeneTex has incorporated recombinant monoclonal antibody technology into its product development platform. This technology has numerous well-documented advantages, with consistency of performance being of paramount significance. The protocol employed is a multi-parameter approach based on fluorescence-activated cell sorting (FACS) to isolate antigen-specific memory B cells from an immunized animal, with subsequent cloning of the antibody variable-region genes into an Immunoglobulin G (IgG) backbone and expression in mammalian cells. The entire development procedure can be completed in weeks.

References

  1. "About Us | GeneTex". www.genetex.com. Retrieved 2019-07-18.
  2. "GeneTex Five Pillars of Antibody Validation".
  3. Uhlen, Mathias; Bandrowski, Anita; Carr, Steven; Edwards, Aled; Ellenberg, Jan; Lundberg, Emma; Rimm, David L.; Rodriguez, Henry; Hiltke, Tara; Snyder, Michael; Yamamoto, Tadashi (October 2016). "A proposal for validation of antibodies". Nature Methods. 13 (10): 823–827. doi:10.1038/nmeth.3995. PMC 10335836. PMID 27595404. S2CID 34259132.
  4. "Recombinant Antibodies | GeneTex". www.genetex.com. Retrieved 2020-10-30.
Categories: